|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CXCL12(SDFlalpha)- CXCR4/CXCR7 pathway inhibition:an emerging sensitizer for anti- cancer therapies? 显示文摘 | Duda DG Kozin SV Kirkpatriek ND | 2011 | Clin Cancer Res2011，17，8： | 1 |
| 2 | Role of eNOS in neovascularization : NO for endothelial progenitor cells显示文摘 | Duda DG Fukumura D Jain RK | 2004 | Trends Mol Med2004，10，： | 1 |
| 3 | Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma 显示文摘 | Lu EC Duda DG Emblem KE | 2015 | J Clin Oncol2015，33，10： | 1 |
| 4 | Lessons from phase Ⅲ clinical trials on anti-VEGF therapy for cancer显示文摘 | Jain RK Duda DG Clark JW | 2006 | Nat Clin Pract Oncol2006，3，1： | 1 |
| 5 | Direct evidence that bevacizumab,an anti-VEGF antibody,up-regulars SDF1 alpha,CXCR4,CXCL6,and neuropilin 1 in tumors from patients with rectal cancer显示文摘 | Xu L Duda DG di Tomaso E | 2009 | Cancer Res2009，69，20： | 1 |
| 6 | Efficacy,safety,and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma:a phase Ⅱ study显示文摘 | Zhu AX Sahani DV Duda DG | 2009 | J Clin Oncol2009，27，18： | 1 |
| 7 | Is vasculogenesis crucial for the regrowth of irradiated tumours显示文摘 | Kozin SV Duda DG Munn LL | 2011 | Nat Rev Cancer2011，11，7： | 1 |
| 8 | Lessons from phaseⅢ clinical trials on anti-VEGF therapy for cancer显示文摘 | Jain PK Duda DG Clark JW | 2006 | Nat Clin Pract Oncol2006，3，1： | 1 |
| 9 | Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma 显示文摘 | Batchelor qF Duda DG di Tomaso E | 2010 | J Clin Oncol2010，28，： | 1 |
| 10 | Normalization of the vasculature for treatment of cancer and other diseases显示文摘 | Goel S Duda DG Xu L | 2011 | Physiol Rev2011，91，： | 1 |
| 11 | Direet evidence that bevaeizumab,an anti -VEGF antibody,up -regulates SDFlalpha,CXCR4,CXCL6,and neuropilin 1 in tumors from patients with rectal cancer 显示文摘 | Xu L Duda DG di Tomaso E | 2009 | Cancer Res2009，69，20： | 1 |
| 12 | Lessons from phase HI clinical trials on anti-VEGF therapy for cancer 显示文摘 | Jain RK Duda DG Clark JW | 2006 | Nat Clin Pract Oncol2006，3，： | 1 |
| 13 | Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor显示文摘 | Hoshida T Sunamura M Duda DG | 2002 | Pancreas2002，25，： | 1 |
| 14 | Lessons from phase Ⅲ clin- ical trials on anti-VEGF therapy for cancer显示文摘 | Jain RK Duda DG Clark JW | 2006 | Nat Clin Pract O- ncol2006，3，1： | 1 |
| 15 | Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocar- cinoma cells显示文摘 | Duda DG Sunamura M Lefter LP | 2003 | Oncogene2003，22，44： | 1 |
| 16 | Malignant cells facilitate lung metastasis by bringing their own soil显示文摘 | Duda DG Duyverman AM Kohno M | 2010 | Proc Natl Acad Sci USA2010，107，21： | 1 |
| 17 | Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy显示文摘 | Duda DG Cohen KS di Tomaso E | 2006 | J Clin Oncol2006，24，9： | 1 |
| 18 | Surrogate markers for antian giogenic therapy and dose-limiting toxicities for bevacizumab withradiation and chemotherapy: continued experience of a phase 1 trial in rectal cancer patients显示文摘 | Willett CG Boucher Y Duda DG | 2005 | J Clin Onco12005，23，31： | 1 |
| 19 | Exploration of Imaging Biomarkers for Predicting Survival of Patients With Ad-vanced Non-Small Cell Lung Cancer Treated With Antiangiogen- ic Chemotherapy 显示文摘 | Hayano K Kulkarni NM Duda DG | 2016 | A JR Am J Roentgenol2016，206，5： | 1 |
| 20 | Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase 1I study 显示文摘 | Zhu AX Sahani DV Duda DG | 2009 | J Clin Oncol2009，27，18： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员